Swayam Prabha, MBA, PhD, MS

Assistant Professor, Department of Experimental and Clinical Pharmacology (ECP)

Swayam Prabha

Contact Info

prabh025@umn.edu

Office Phone 612-626-3545

Office Address:
9-127D Weaver-Densford Hall

Mailing Address:
University of Minnesota
College of Pharmacy
Room 5-130 WDH
308 Harvard St SE
Minneapolis, MN 55455

PhD of Pharmaceutics, University of Nebraska Medical Center, 2004

MBA, University of Minnesota, Carlson School of Management, 2011

Master of Technology, Banaras Hindu University, 1999

Bachelor of Pharmacy, Delhi University, 1997

Summary

Awards & Recognition

  • First Place, Medtronic Interdisciplinary Case Competition to develop “Go-to Market” strategy, 2012
  • Medical Industry Leadership Institute Fellowship, 2010-2011
  • Norman and Bernice Harris award for excellence in cancer research, 2004
  • AAPS Graduate Symposium Award in Biotechnology, 2004
  • Norman and Bernice Harris award for excellence in cancer research, 2002
  • Pre-doctoral Fellowship awarded by the Department of Defense, USA, 2002-2005
  • Widaman Fellowship Supplement from University of Nebraska Medical Center, 2002-2005
  • Best oral presentation at Midwest Student Biomedical Research Forum, NE, 2004
  • First place Oral Presentation at Midwest Student Biomedical Research Forum, NE, 2001
  • Junior Research Fellowship awarded by University Grants Commission, India, 1997-1999

Research

Research Summary/Interests

My primary expertise is in dosage form design, formulation and process development, technical operations and technology transfer, and product development. I am hired at University of Minnesota in part to implement a newly formed Center for Translational Drug Delivery (CTDD), housed in the College of Pharmacy. As is well known, successful translation of drugs and biological macromolecules into the clinic requires proper device design for delivery, and the purpose of CTDD is to address unmet formulation and drug delivery needs for partners on campus and in industry.

Women's Health and Chemoprevention:
Ovarian cancer is one of the most common cancers in women of all ages in the United States. Even though there has been some decline in mortality over the last decade, the number of women that die from the disease is still significantly high. The current drug therapy for ovarian cancer is ineffective in patients who present with advanced disease (peritoneal metastases, for example). Thus, new treatments that can either inhibit the progression of the disease and/or those that are effective against advanced disease are urgently needed. We propose to study the effectiveness of simultaneously delivering two agents, one of which blocks new blood vessel formation in the tumors (P125Aendostatin gene) and another that kills cancer cells directly (carboplatin), for the treatment of ovarian cancer. There are a number of ways to introduce such treatments to the tumor tissue. Currently used methods suffer from concerns of toxicity, while others are ineffective even after multiple injections because the body recognizes and rejects them as foreign. Therefore, it is important to develop drug and gene delivery systems that are effective and non-toxic. We propose to use artificial viral-like particles, called nanoparticles, to safely co-deliver the gene and drug of interest to the tumor.

Chronic Wounds:
Chronic wounds are prevalent throughout the world, with few effective methods of treatment. Wounds associated with diabetes are difficult to heal and often stay unhealed leading to higher morbidity and mortality in the diabetic population. We are working on developing a localized drug delivery mechanism that will allow

therapeutic molecules to be delivered specifically to wound sites. The overall goal is to develop an effective and convenient non-surgical therapy for diabetic wound healing. Targeted, wound-specific drug delivery has a very large market (9.18 million patients in the U.S.) when considering both a specialized treatment (chronic diabetic wound) and the broader ramifications of compromised healing or recurrent wounds. Additionally, if the chronic wounds can be treated, then the need for amputation and additional medical services will be reduced, which will ultimately reduce total health care costs.

  • Infectious diseases
  • Chronic wounds
  • Chemoprevention
  • Women's health
  • Drug delivery
  • Lipid formulations
  • Nanotechnology
  • Polymeric films

Publications

PEER-REVIEWED PUBLICATIONS

  • Prabha, S., Zhou, W. Z., Panyam, J. and Labhasetwar, V. (2002) Particle size dependency of nanoparticle mediated gene transfection: Effect of particle size. Int J Pharm, 244 (1-2): 105-115.
  • Panyam, J., Zhou, W.Z., Prabha, S., Sahoo, S. and Labhasetwar, V. (2002) Rapid endo-lysosomal escape of poly (D,L-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J, 16(10): 1217-1226.
  • Sahoo, S. K., Panyam, J., Prabha, S. and Labhasetwar V. (2002) Residual polyvinyl alcohol associated with poly (DL-lactide-co-glycolide) nanoparticles affects their physical and cellular uptake properties. J Control Release, 82(10): 105-114.
  • Panyam, J., Sahoo, S.K., Prabha, S. and Labhasetwar, V. (2003) Fluorescence and electron microscopy probes for poly(D,L-lactide-co-glycolide) nanoparticles. Int J Pharm, 262, 1-11.
  • Prabha, S. and Labhasetwar, V. (2004) Critical determinants in nanoparticle-mediated gene expression. Pharm Res, 21 (2), 354-63.
  • Prabha, S. and Labhasetwar, V. (2004) Nanoparticle-Mediated Sustained Wild Type-P53 Gene Delivery Results In Greater Antiproliferative Activity In Breast Cancer Cells, Molecular Pharmaceutics, 1(3), 211-19.
  • Prabha, S., Ma, W., and Labhasetwar, V. (2004) Biodegradable Nanoparticles as Gene Expression Vector in Polymeric Gene Delivery: Principles and Applications edited by Mansoor Amiji, CRC Press, 357-67.
  • Prabha, S., Sharma B and Labhasetwar V. (2012). Inhibition of tumor angiogenesis and growth by nanoparticle-mediated p53 gene therapy in mice, Cancer gene therapy 19(8):530-7.